Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate - Morningstar
Bristol Myers Squibb presents 10-year CheckMate -067 data showing durable survival benefit with Opdivo plus Yervoy in advanced melanoma, with 43% of patients alive at 10 years, compared to 25% a decade ago. Data published in The New England Journal of Medicine.
Reference News
Bristol Myers Squibb presents 10-year CheckMate -067 data showing durable survival benefit with Opdivo plus Yervoy in advanced melanoma, with 43% of patients alive at 10 years, compared to 25% a decade ago. Data published in The New England Journal of Medicine.
10-year follow-up data from Bristol Myers Squibb's CheckMate-067 trial showed 43% of melanoma patients alive after receiving Opdivo and Yervoy combo, with median overall survival of 71.9 months. BMS also ended collaboration with Immatics, returning development of IMA401 to the biotech.